

Not driver metastatic NSCLC

Negative PD-L1
(<1%)

Low PD-L1
(1-49%)

High PD-L1
(≥50%)

Squamous

Non Squamous

Squamous

Non Squamous

Squamous

Non
Squamous

KEYNOTE 407
Pembro-platinum –
Paclitaxel or nab paclitaxel

KEYNOTE 189
Pembro-platinum –
pemetrexed

KEYNOTE 407
Pembro-platinum –
Paclitaxel or nab paclitaxel

KEYNOTE 189
Pembro-platinum –
pemetrexed

KEYNOTE 024
Pembrolizumab single agent

IMPOWER 132
Atezolizumab-Carboplatin-
pemetrexed

IMPOWER 131
Atezolizumab-Carboplatin-
paclitaxel

IMPOWER 132
Atezolizumab-Carboplatin-
pemetrexed

IMPOWER 131
Atezolizumab-Carboplatin-
paclitaxel

IMPOWER 110
Atezolizumab single agent

IMPOWER 150
Atezolizumab-Carboplatin-
paclitaxel - bevacizumab

IMPOWER 150
Atezolizumab-Carboplatin-
paclitaxel - bevacizumab

EMPOWER-Lung 1
Cemiplimab single agent

KEYNOTE 042
Pembrolizumab single agent

CHECK MATE 227
Ipilimumab with nivolumab

POSEIDON
Tremelimumab plus durvalumab plus CT

CHECK MATE 9LA
Ipilimumab with nivolumab with 2 cycles platinum doublet